|
1
|
Klinge CM: Estrogen receptor interaction
with estrogen response elements. Nucleic Acids Res. 29:2905–2919.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Platet N, Cathiard AM, Gleizes M and
Garcia M: Estrogens and their receptors in breast cancer
progression: A dual role in cancer proliferation and invasion. Crit
Rev Oncol Hematol. 51:55–67. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin NU and Winer EP: Advances in adjuvant
endocrine therapy for postmenopausal women. J Clin Oncol.
26:798–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cuzick J, Sestak I, Baum M, Buzdar A,
Howell A, Dowsett M and Forbes JF: ATAC/LATTE investig: Effect of
anastrozole and tamoxifen as adjuvant treatment for early-stage
breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol.
11:1135–1141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
BIG 1–98 Collaborative Group, . Mouridsen
H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith
I, Mauriac L, Forbes J, Price KN, et al: Letrozole therapy alone or
in sequence with tamoxifen in women with breast cancer. N Engl J
Med. 361:766–776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Regan MM, Neven P, Giobbie-Hurder A,
Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I,
Wardley A, et al: Assessment of letrozole and tamoxifen alone and
in sequence for postmenopausal women with steroid hormone
receptor-positive breast cancer: The BIG 1–98 randomised clinical
trial at 8.1 years median follow-up. Lancet Oncol. 12:1101–1108.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Becker MA, Ibrahim YH, Cui X, Lee AV and
Yee D: The IGF pathway regulates ERα through a S6K1-dependent
mechanism in breast cancer cells. Mol Endocrinol. 25:516–528. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamnik RL, Digilova A, Davis DC, Brodt ZN,
Murphy CJ and Holz MK: S6 kinase 1 regulates estrogen receptor
alpha in control of breast cancer cell proliferation. J Biol Chem.
284:6361–6369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boulay A, Rudloff J, Ye J, Zumstein-Mecker
S, O'Reilly T, Evans DB, Chen S and Lane HA: Dual inhibition of
mTOR and estrogen receptor signaling in vitro induces cell death in
models of breast cancer. Clin Cancer Res. 11:5319–5328. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miller TW, Hennessy BT, González-Angulo
AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y
and Arteaga CL: Hyperactivation of phosphatidylinositol-3 kinase
promotes escape from hormone dependence in estrogen
receptor-positive human breast cancer. J Clin Invest.
120:2406–2413. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orti E, Bodwell JE and Munck A:
Phosphorylation of steroid hormone receptors. Endocr Rev.
13:105–128. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fox EM, Kuba MG, Miller TW, Davies BR and
Arteaga CL: Autocrine IGF-I/insulin receptor axis compensates for
inhibition of AKT in ER-positive breast cancer cells with
resistance to estrogen deprivation. Breast Cancer Res. 15:R552013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Le Goff P, Montano MM, Schodin DJ and
Katzenellenbogen BS: Phosphorylation of the human estrogen
receptor. Identification of hormone-regulated sites and examination
of their influence on transcriptional activity. J Biol Chem.
269:4458–4466. 1994.PubMed/NCBI
|
|
14
|
Arnold SF, Obourn JD, Jaffe H and Notides
AC: Serine 167 is the major estradiol-induced phosphorylation site
on the human estrogen receptor. Mol Endocrinol. 8:1208–1214. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haystead TA, Sim AT, Carling D, Honnor RC,
Tsukitani Y, Cohen P and Hardie DG: Effects of the tumour promoter
okadaic acid on intracellular protein phosphorylation and
metabolism. Nature. 337:78–81. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suganuma M, Fujiki H, Suguri H, Yoshizawa
S, Hirota M, Nakayasu M, Ojika M, Wakamatsu K, Yamada K and
Sugimura T: Okadaic acid: An additional
non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc
Natl Acad Sci USA. 85:pp. 1768–1771. 1988, View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hayashi T, Hikichi M, Utsumi T, Harada N
and Yukitake J: Inhibition of PP2A in MCF-7 cells leads to
hormone-independent growth. Int J Anal Bio-Sci. 4:1–5. 2016.
View Article : Google Scholar
|
|
18
|
Mumby M: PP2A: Unveiling a reluctant tumor
suppressor. Cell. 130:21–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Westermarck J and Hahn WC: Multiple
pathways regulated by the tumor suppressor PP2A in transformation.
Trends Mol Med. 14:152–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kong M, Fox CJ, Mu J, Solt L, Xu A,
Cinalli RM, Birnbaum MJ, Lindsten T and Thompson CB: The
PP2A-associated protein alpha4 is an essential inhibitor of
apoptosis. Science. 306:695–698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sontag E: Protein phosphatase 2A: The
trojan horse of cellular signaling. Cell Signal. 13:7–16. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Janssens V and Goris J: Protein
phosphatase 2A: A highly regulated family of serine/threonine
phosphatases implicated in cell growth and signalling. Biochem J.
353:417–439. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eichhorn PJ, Creyghton MP and Bernards R:
Protein phosphatase 2A regulatory subunits and cancer. Biochim
Biophys Acta. 1795:1–15. 2009.PubMed/NCBI
|
|
24
|
Shim WS, Conaway M, Masamura S, Yue W,
Wang JP, Kmar R and Santen RJ: Estradiol hypersensitivity and
mitogen-activated protein kinase expression in long-term estrogen
deprived human breast cancer cells in vivo. Endocrinology.
141:396–405. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Santen RJ, Song RX, Zhang Z, Kumar R, Jeng
MH, Masamura A, Lawrence J Jr, Berstein L and Yue W: Long-term
estradiol deprivation in breast cancer cells up-regulates growth
factor signaling and enhances estrogen sensitivity. Endocr Relat
Cancer. 12 Suppl 1:S61–S73. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Walter P, Green S, Greene G, Krust A,
Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M,
et al: Cloning of the human estrogen receptor cDNA. Proc Natl Acad
Sci USA. 82:pp. 7889–7893. 1985, View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levenson AS and Jordan VC: MCF-7: The
first hormone-responsive breast cancer cell line. Cancer Res.
57:3071–3078. 1997.PubMed/NCBI
|
|
28
|
Baldacchino S, Saliba C, Petroni V, Fenech
AG, Borg N and Grech G: Deregulation of the phosphatase, PP2A is a
common event in breast cancer, predicting sensitivity to FTY720.
EPMA J. 5:32014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duronio RJ and Xiong Y: Signaling pathways
that control cell proliferation. Cold Spring Harb Perspect Biol.
5:a0089042013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bononi A, Agnoletto C, De Marchi E, Marchi
S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F,
Rimessi A and Pinton P: Protein kinases and phosphatases in the
control of cell fate. Enzyme Res. 2011:3290982011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mumby MC and Walter G: Protein
serine/threonine phosphatases: Structure, regulation, and functions
in cell growth. Physiol Rev. 73:673–699. 1993.PubMed/NCBI
|
|
32
|
Zhao Q, Zhao M, Parris AB, Xing Y and Yang
X: Genistein targets the cancerous inhibitor of PP2A to induce
growth inhibition and apoptosis in breast cancer cells. Int J
Oncol. 49:1203–1210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Holmes CF, Luu HA, Carrier F and Schmitz
FJ: Inhibition of protein phosphatases-1 and −2A with
acanthifolicin. Comparison with diarrhetic shellfish toxins and
identification of a region on okadaic acid important for
phosphatase inhibition. FEBS Lett. 270:216–218. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY
and Chiang CW: Regulation of phosphorylation of Thr-308 of Akt,
cell proliferation, and survival by the B55alpha regulatory subunit
targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol
Chem. 283:1882–1892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peterson RT, Desai BN, Hardwick JS and
Schreiber SL: Protein phosphatase 2A interacts with the 70-kDa S6
kinase and is activated by inhibition of FKBP12-rapamycinassociated
protein. Proc Natl Acad Sci USA. 96:pp. 4438–4442. 1999, View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hurvitz SA and Pietras RJ: Rational
management of endocrine resistance in breast cancer: A
comprehensive review of estrogen receptor biology, treatment
options, and future directions. Cancer. 113:2385–2397. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li L, Zhang J, Xiong N, Li S, Chen Y, Yang
H, Wu C, Zeng H and Liu Y: Notch-1 signaling activates NF-κB in
human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT
pathway. Med Oncol. 33:332016. View Article : Google Scholar : PubMed/NCBI
|
